P160 the First Phase 2A Proof-Of-Concept Study of a Selective NLRP3 Inflammasome Inhibitor, Dapansutrile™ (OLT1177™), in Acute Gout

doi 10.1136/annrheumdis-2018-ewrr2019.142
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ Publishing Group Ltd and European League Against Rheumatism

Related search

P159/O30 OLT1177™, an Oral NLRP3 Inflammasome Inhibitor, Inhibits Acute Joint Inflammation and Circulating IL 1β During Gout Flares in Humans

2019English

A Study Case in Photoepilation, the HPPL™ and IFL™ Technologies

Dermatology Reports
Dermatology
2017English

Students’ Perception on Their Motivation in Learning English (The Analysis Students’ Motivation Based on Maslow’s Concept)

Biormatika : Jurnal ilmiah fakultas keguruan dan ilmu pendidikan
2019English

Ledipasvir and Sofosbuvir for Hepatitis C Genotype 4: A Proof-Of-Concept, Single-Centre, Open-Label Phase 2a Cohort Study

The Lancet Infectious Diseases
Infectious Diseases
2015English

Does Colchicine Work? The Results of the First Controlled Study in Acute Gout

Australian and New Zealand Journal of Medicine
1987English

Cellular Localization of NLRP3 Inflammasome

Protein & Cell
BiochemistryBiotechnologyDrug DiscoveryCell BiologyMedicine
2013English

Do Not €˜Hit and Miss’ or €˜Spray and Pray’, Diagnose First

Journal of Economics and Behavioral Studies
2012English

RORγ Regulates the NLRP3 Inflammasome

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2018English

A First in Human Study of the Selective Cardiac Myosin Inhibitor, CK-3773274

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy